Boston Scientific Corp (BSX)vsEdwards Lifesciences Corp (EW)
BSX
Boston Scientific Corp
$43.50
-1.85%
HEALTHCARE · Cap: $60.84B
EW
Edwards Lifesciences Corp
$93.26
+1.36%
HEALTHCARE · Cap: $52.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 224% more annual revenue ($21.07B vs $6.51B). BSX leads profitability with a 16.6% profit margin vs 15.4%. BSX appears more attractively valued with a PEG of 0.63. BSX earns a higher WallStSmart Score of 62/100 (C+).
BSX
Buy62
out of 100
Grade: C+
EW
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-7.2%
Fair Value
$39.17
Current Price
$43.50
$4.33 premium
Margin of Safety
+68.5%
Fair Value
$251.45
Current Price
$93.26
$158.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.2%
Generating 1.3B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Strong operational efficiency at 29.8%
Areas to Watch
1.4% revenue growth
Distress zone — elevated risk
Earnings declined 21.5%
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 16.6% and operating margin at 20.2%. PEG of 0.63 suggests the stock is reasonably priced for its growth.
Bull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 54.6x leaves little room for execution misses.
Key Dynamics to Monitor
BSX profiles as a value stock while EW is a mature play — different risk/reward profiles.
EW carries more volatility with a beta of 0.86 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (62/100 vs 53/100), backed by strong 16.6% margins. EW offers better value entry with a 68.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?